Novo Nordisk Shares Drop 6% Despite Raised 2026 Sales Guidance, as Wegovy Pill Keeps Beating Lilly's Foundayo

Novo Nordisk's stock got punished Tuesday for good news that wasn't good enough.

U.S.-listed shares fell more than 6% by 3 p.m. ET after the Danish drugmaker released preliminary second-quarter numbers and an updated 2026 outlook ahead of its full earnings report scheduled for Wednesday, August 5, according to IBTimes. Novo now expects full-year adjusted sales at constant exchange rates to range from a 6% decline to flat growth. That's a real improvement from its prior guidance of a 4% to 12% decline.

Adjusted operating profit guidance also improved, now projected between a 6% decline and flat, up from the previous range of down 4% to 12%.

Investors shrugged. The underlying quarter was actually solid. Novo reported second-quarter sales of 78.49 billion Danish kroner, roughly $12.09 billion, up 3% at constant exchange rates and up 7% on an adjusted basis, per IBTimes. Adjusted operating profit rose 11% at constant exchange rates to 33.39 billion kroner.

None of that mattered much once traders read the fine print: Novo is still telling the market sales and profit could shrink this year compared to 2025. When a company's best-case scenario is "flat," Wall Street doesn't throw a parade.

The Wegovy Pill Is Actually Working

Novo's oral version of Wegovy is winning, and winning clearly.

Novo became the first major drugmaker to launch an oral GLP-1 obesity pill when it rolled out the Wegovy tablet in the U.S. in January, beating Eli Lilly's oral rival Foundayo (orforglipron) to market, according to IBTimes and The Independent.

The gap hasn't closed. Fierce Pharma's Oral GLP-1 Tracker, using IQVIA prescription data cited by Citi, reported that weekly total prescriptions for oral Wegovy hit roughly 171,700 as of the week ending July 31, a new record and up 1.1% from the prior best week. Foundayo, by contrast, reached a new high of 29,388 weekly prescriptions in the same period, its third straight week of growth but still less than a fifth of Wegovy's pill volume.

Barclays analyst James Gordon told The Independent that "one of the concerns had been that orforglipron from Lilly was going to come along and make things a lot tougher for oral Wegovy. But so far... orforglipron doesn't really seem to have impacted the product."

Barclays did flag a caveat worth taking seriously: the IQVIA figures likely understate real Foundayo demand because they exclude certain distribution and telehealth channels, according to The Independent and Fierce Pharma. Jefferies analysts have modeled roughly $71 million in U.S. Foundayo sales for the quarter based on the available data, a number that could shift once Lilly reports actual results.

Context Nobody Should Skip

Novo had fallen far before this. The company spent 2025 on the defensive, cutting guidance four times, replacing its CEO, and eliminating 9,000 jobs as Eli Lilly's Zepbound and Mounjaro ate its market share, The Independent reported.

Novo shares have climbed about 35% off their March low. Morten Gregersen, chief portfolio manager at Danish asset manager Formuepleje and a Novo shareholder, told The Independent that "Novo is a different Novo today than a year ago. They're much more consumer-oriented and they've become much more aggressive."

That aggression includes a legal fight: Novo has filed suit against Lilly alleging misleading marketing in the U.S. market, according to The Independent. No court ruling has been reported, and the allegations remain unproven claims in litigation, not an established finding.

What's Actually at Stake This Week

Wegovy still commands 40.6% of the total obesity-drug market by prescription volume, per Fierce Pharma's tracker, even after a slight 0.2% weekly dip. Lilly's Zepbound, meanwhile, gained ground, with total scripts up 1.9% week over week. The entire GLP-1 category, covering both diabetes and obesity uses, grew 1.1% sequentially.

The obesity drug market as a whole is projected by analysts to exceed $100 billion in the U.S. alone by the end of the decade, according to The Independent's reporting.

Full second-quarter results and forward commentary from both companies are scheduled for Wednesday, August 5. That's when analysts expect clarity on whether Foundayo's recent prescription growth reflects genuine momentum or a smaller base catching up from a low starting point, and whether Novo's improved but still cautious 2026 guidance holds up under further scrutiny from investors who clearly wanted more than "better than before."